A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer

NCT06799286 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Carcinoma

Interventions

DRUG: BMS-986489

Sponsor

Bristol-Myers Squibb